Quick Takeaways
- Pontifax Management 4 G.P. (2015) Ltd. filed SCHEDULE 13G for Agomab Therapeutics NV Common Shares, no nominal value per share.
- Disclosed ownership: 6.8%.
- Date of event: 31 Mar 2026.
Pontifax Management 4 G.P. (2015) Ltd. - 31 Mar 2026 SCHEDULE 13G Report for Agomab Therapeutics NV Common Shares, no nominal value per share
- Filing Manager
- Pontifax Management 4 G.P. (2015) Ltd.
- Reporting Manager
- Pontifax VI G.P. L.P.
- Shares outstanding
- 48,615,382 shares
- Disclosed Ownership
- 3,305,846 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G
- Filing time
- 16 Apr 2026, 09:14:33 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Pontifax Management 4 G.P. (2015) Ltd. disclosed 6.8% ownership in Agomab Therapeutics NV Common Shares, no nominal value per share on 31 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 16 Apr 2026, 09:14.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Pontifax VI G.P. L.P. | 6.8% | 3,305,846 | 0 | 3,305,846 | /s/ Pontifax Management 4 G.P. (2015) Ltd. | Pontifax Management 4 G.P. (2015) Ltd./General Partner | |
| Pontifax Management 4 G.P. (2015) Ltd. | 6.8% | 3,305,846 | 0 | 3,305,846 | /s/ Ran Nussbaum | Ran Nussbaum/Director | |
| Ran Nussbaum | 6.8% | 3,305,846 | 0 | 3,305,846 | /s/ Ran Nussbaum | Ran Nussbaum | |
| Tomer Kariv | 6.8% | 3,305,846 | 0 | 3,305,846 | /s/ Tomer Kariv | Tomer Kariv |